The medication Mounjaro, developed by Eli Lilly, has significantly decreased the likelihood of diabetes-related issues.
Eli Lilly's weight loss medication Mounjaro, specifically Tirzepatide, slashes diabetes risk by 94% in long-term trial. For adults with prediabetes and obesity or excess weight, this decrease was seen with drug treatment, according to Lilly's announcement on Tuesday.
In this research including 1032 participants, an average weight drop of 22.9% was seen versus a 2.1% reduction with a placebo. Tirzepatide serves as the active component in Lilly's diabetes and weight loss injection, Mounjaro, which goes by Zepbound in the U.S.
As Jeff Emmick, responsible for product development at Lilly, put it, "Obesity, a persistent health issue, exposes approximately 900 million adults globally to elevated risks of other disorders such as type 2 diabetes." Tirzepatide decreased the risk of experiencing type 2 diabetes by 94% and promoted continued weight loss throughout the three-year treatment phase. Emmick's comments highlight the potentially significant impact of long-term therapy for individuals battling obesity and prediabetes.
Both Lilly and rival Novo Nordisk eyes expanding their obesity medication applications to conditions like sleep apnea and cardiovascular disease. The pharmaceutical giants aim to change the perception of their weight loss injections, moving away from labeling them as mere lifestyle medications. Presently in Germany, these medications are not covered under statutory health insurance.
Tackling obesity's associated risks is crucial, as it exposes individuals to various health issues, including a higher risk of type 2 diabetes. The long-term use of Tirzepatide, the active component in Mounjaro, led to a 94% decrease in the risk of developing type 2 diabetes.
